ATE555788T1 - Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität - Google Patents
Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivitätInfo
- Publication number
- ATE555788T1 ATE555788T1 AT07812295T AT07812295T ATE555788T1 AT E555788 T1 ATE555788 T1 AT E555788T1 AT 07812295 T AT07812295 T AT 07812295T AT 07812295 T AT07812295 T AT 07812295T AT E555788 T1 ATE555788 T1 AT E555788T1
- Authority
- AT
- Austria
- Prior art keywords
- glucocerebrosidase
- enhancement
- beta
- neurological diseases
- treating neurological
- Prior art date
Links
- 102000004547 Glucosylceramidase Human genes 0.000 title abstract 7
- 108010017544 Glucosylceramidase Proteins 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 4
- 230000000694 effects Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
- 108010006519 Molecular Chaperones Proteins 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 2
- 102000005431 Molecular Chaperones Human genes 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81595206P | 2006-06-23 | 2006-06-23 | |
| PCT/US2007/072016 WO2007150064A2 (en) | 2006-06-23 | 2007-06-25 | METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE555788T1 true ATE555788T1 (de) | 2012-05-15 |
Family
ID=38834440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07812295T ATE555788T1 (de) | 2006-06-23 | 2007-06-25 | Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US7829579B2 (https=) |
| EP (1) | EP2040548B1 (https=) |
| JP (1) | JP5303458B2 (https=) |
| KR (1) | KR101402554B1 (https=) |
| AT (1) | ATE555788T1 (https=) |
| AU (1) | AU2007260812B2 (https=) |
| BR (1) | BRPI0713442A2 (https=) |
| CA (1) | CA2656643C (https=) |
| DK (1) | DK2040548T3 (https=) |
| ES (1) | ES2387845T3 (https=) |
| IL (1) | IL196151A (https=) |
| MX (1) | MX2009000032A (https=) |
| PT (1) | PT2040548E (https=) |
| WO (1) | WO2007150064A2 (https=) |
| ZA (1) | ZA200900270B (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| WO2007150064A2 (en) | 2006-06-23 | 2007-12-27 | Amicus Therapeutics, Inc. | METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE |
| GB0622702D0 (en) * | 2006-11-15 | 2006-12-27 | Univ Dundee | Selective glycosidase inhibitors |
| EP2154969B1 (en) | 2007-05-16 | 2015-11-18 | The Brigham and Women's Hospital, Inc. | Treatment of synucleinopathies |
| US8540985B2 (en) * | 2008-06-26 | 2013-09-24 | Orphazyme Aps | Use of Hsp70 as a regulator of enzymatic activity |
| GB2480159A (en) * | 2008-11-14 | 2011-11-09 | Parkinson S Inst | Compositions and methods for the treatment of altered a-synuclein function |
| BRPI1010517A2 (pt) * | 2009-04-09 | 2017-01-31 | Amicus Therapeutics Inc | métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal |
| BRPI1015472A2 (pt) * | 2009-04-09 | 2015-11-24 | Amicus Therapeutics Inc | métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central |
| GB0906159D0 (en) * | 2009-04-09 | 2009-05-20 | Summit Corp Plc | Drug combination for the treatment of proteostatic diseases |
| US9206457B2 (en) * | 2009-05-26 | 2015-12-08 | Amicus Therapeutics, Inc. | Utilization of pharmacological chaperones to improve manufacturing and purification of biologics |
| AU2010254092B2 (en) * | 2009-05-26 | 2015-11-12 | Amicus Therapeutics, Inc. | Utilization of pharmacological chaperones to improve manufacturing and purification of biologics |
| NZ713967A (en) * | 2009-07-28 | 2017-01-27 | Shire Human Genetic Therapies | Compositions and methods for treating gaucher disease |
| KR101880411B1 (ko) | 2009-10-19 | 2018-07-19 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 중추신경계의 퇴행성 질환을 예방 및/또는 치료하는 신규 조성물 |
| US9044437B2 (en) * | 2009-10-19 | 2015-06-02 | Amicus Therapeutics, Inc. | Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases |
| SI2995306T1 (sl) | 2009-10-19 | 2019-04-30 | Amicus Therapeutics, Inc. | Novi sestavki za preprečevanje in/ali zdravljenje motenj lizosomskega shranjevanja |
| RU2013125923A (ru) | 2010-11-30 | 2015-01-10 | Орфазиме Апс | СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70 |
| HUE044867T2 (hu) | 2011-05-12 | 2019-11-28 | Proteostasis Therapeutics Inc | Proteosztázis szabályzók |
| EP2533051A1 (en) | 2011-06-06 | 2012-12-12 | Centogene GmbH | Method for the diagnosis of Gaucher's disease |
| CA2840224C (en) | 2011-06-22 | 2019-08-13 | The General Hospital Corporation | Treatment of proteinopathies |
| EP2806875B1 (en) | 2012-01-25 | 2017-07-19 | Proteostasis Therapeutics, Inc. | Proteasome activity modulating compounds |
| AU2013337354A1 (en) * | 2012-11-05 | 2015-05-21 | Genzyme Corporation | Compositions and methods for treating proteinopathies |
| WO2014089449A1 (en) * | 2012-12-07 | 2014-06-12 | Rush University Nedical Center | Composition and method for treating neuronal ceroid lipofuscinosis |
| US9796680B2 (en) | 2013-12-23 | 2017-10-24 | Alectos Therapeutics Inc. | Glucocerebrosidase modulators and uses thereof |
| US9675627B2 (en) | 2014-04-14 | 2017-06-13 | Amicus Therapeutics, Inc. | Dosing regimens for treating and/or preventing cerebral amyloidoses |
| US10709700B2 (en) | 2014-09-15 | 2020-07-14 | Orphazyme A/S | Arimoclomol formulation |
| EP4406616A3 (en) | 2014-11-06 | 2024-11-06 | Bial-R&D Investments, S.A. | Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders |
| CA2985235A1 (en) | 2015-05-07 | 2016-11-10 | Shire Human Genetic Therapies, Inc. | Glucocerebrosidase gene therapy for parkinson's disease |
| AU2017246455B2 (en) | 2016-04-06 | 2021-09-30 | Bial - R&D Investments, S.A. | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| EP3440081A4 (en) | 2016-04-06 | 2019-09-18 | Lysosomal Therapeutics Inc. | PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER |
| CA3020305A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| EP3442530A1 (en) | 2016-04-13 | 2019-02-20 | Orphazyme A/S | Heat shock proteins and cholesterol homeostasis |
| KR20210059796A (ko) | 2016-04-29 | 2021-05-25 | 오르파짐 에이/에스 | 글루코세레브로시다제 연관 장애를 치료하기 위한 아리모클로몰 |
| KR102530515B1 (ko) | 2016-05-05 | 2023-05-09 | 비알 - 알&디 인베스트먼츠, 에스.에이. | 치환된 이미다조[1,2-b]피리다진, 치환된 이미다조[1,5-b]피리다진, 관련 화합물, 및 의학적 장애의 치료에서의 그의 용도 |
| EP3264092A1 (en) * | 2016-07-01 | 2018-01-03 | Centogene AG | Use of lyso-gb1 as druggable target |
| KR20240171186A (ko) | 2017-10-26 | 2024-12-06 | 다케다 야쿠힌 고교 가부시키가이샤 | 글루코세레브로시다제 및 이소파고민을 포함하는 제제 |
| CN108428452B (zh) | 2018-03-14 | 2019-12-13 | 百度在线网络技术（北京）有限公司 | 终端支架和远场语音交互系统 |
| WO2020006269A1 (en) | 2018-06-27 | 2020-01-02 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| JP7561632B2 (ja) | 2018-06-27 | 2024-10-04 | キネタ， インコーポレイテッド | プロテアソーム活性増強化合物 |
| US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| SG11202105606XA (en) * | 2018-12-05 | 2021-06-29 | Univ Washington | Methods of detecting, preventing, reversing, and treating neurological diseases |
| WO2020219874A1 (en) * | 2019-04-25 | 2020-10-29 | Shire Human Genetic Therapies, Inc. | Isofagomine salts, methods of use and formulations |
| CN111450306B (zh) * | 2020-03-06 | 2021-11-19 | 大连理工大学 | 外用纳米羟基磷灰石/聚多巴胺湿黏附型止血粉及其制备方法 |
| KR20230128462A (ko) | 2020-11-19 | 2023-09-05 | 제브라 덴마크 에이/에스 | 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정 |
| EP4329881A4 (en) * | 2021-04-30 | 2025-06-11 | Vanqua Bio, Inc. | Small molecule modulators of glucocerebrosidase activity and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2268904A1 (en) * | 1996-10-15 | 1998-04-23 | Imperial College Of Science, Technology And Medicine | Diagnosis of spongiform encephalopathy |
| GB2333362B (en) | 1996-10-15 | 2001-05-16 | Imperial College | Typing and diagnosis of spongiform encephalopathy |
| US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| EP2857036B1 (en) | 2003-01-31 | 2016-12-21 | Mount Sinai School of Medicine of New York University | Combination therapy for treating protein deficiency disorders |
| CA2545433A1 (en) | 2003-11-12 | 2005-05-26 | Amicus Therapeutics Inc. | Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease |
| AU2006254796B2 (en) | 2005-06-08 | 2012-08-16 | Amicus Therapeutics, Inc. | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes |
| PL1860101T3 (pl) * | 2006-05-24 | 2011-10-31 | Amicus Therapeutics Inc | Sól winianu izofagominy i sposoby zastosowania |
| WO2007150064A2 (en) | 2006-06-23 | 2007-12-27 | Amicus Therapeutics, Inc. | METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE |
| CA2688850C (en) | 2007-05-22 | 2015-08-11 | Amicus Therapeutics, Inc. | New method for preparing isofagomine and its derivatives |
-
2007
- 2007-06-25 WO PCT/US2007/072016 patent/WO2007150064A2/en not_active Ceased
- 2007-06-25 AT AT07812295T patent/ATE555788T1/de active
- 2007-06-25 EP EP20070812295 patent/EP2040548B1/en active Active
- 2007-06-25 US US11/768,043 patent/US7829579B2/en active Active
- 2007-06-25 PT PT07812295T patent/PT2040548E/pt unknown
- 2007-06-25 AU AU2007260812A patent/AU2007260812B2/en not_active Ceased
- 2007-06-25 KR KR1020097001465A patent/KR101402554B1/ko not_active Expired - Fee Related
- 2007-06-25 JP JP2009518489A patent/JP5303458B2/ja not_active Expired - Fee Related
- 2007-06-25 MX MX2009000032A patent/MX2009000032A/es active IP Right Grant
- 2007-06-25 DK DK07812295T patent/DK2040548T3/da active
- 2007-06-25 ES ES07812295T patent/ES2387845T3/es active Active
- 2007-06-25 CA CA2656643A patent/CA2656643C/en not_active Expired - Fee Related
- 2007-06-25 BR BRPI0713442-8A patent/BRPI0713442A2/pt not_active Application Discontinuation
-
2008
- 2008-12-23 IL IL196151A patent/IL196151A/en active IP Right Grant
-
2009
- 2009-01-13 ZA ZA2009/00270A patent/ZA200900270B/en unknown
-
2010
- 2010-11-08 US US12/941,468 patent/US9119845B2/en active Active
-
2014
- 2014-08-26 US US14/469,008 patent/US9402837B2/en active Active
-
2016
- 2016-08-01 US US15/225,029 patent/US10064851B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20110052613A1 (en) | 2011-03-03 |
| AU2007260812B2 (en) | 2012-08-16 |
| ZA200900270B (en) | 2011-02-23 |
| DK2040548T3 (da) | 2012-08-13 |
| AU2007260812A1 (en) | 2007-12-27 |
| IL196151A0 (en) | 2009-11-18 |
| US20080009516A1 (en) | 2008-01-10 |
| IL196151A (en) | 2015-08-31 |
| JP5303458B2 (ja) | 2013-10-02 |
| CA2656643A1 (en) | 2007-12-27 |
| KR20090021393A (ko) | 2009-03-03 |
| EP2040548A2 (en) | 2009-04-01 |
| CA2656643C (en) | 2015-08-25 |
| US7829579B2 (en) | 2010-11-09 |
| US9402837B2 (en) | 2016-08-02 |
| BRPI0713442A2 (pt) | 2012-03-06 |
| ES2387845T3 (es) | 2012-10-02 |
| KR101402554B1 (ko) | 2014-06-19 |
| PT2040548E (pt) | 2012-08-02 |
| JP2009541489A (ja) | 2009-11-26 |
| EP2040548B1 (en) | 2012-05-02 |
| US9119845B2 (en) | 2015-09-01 |
| US20150025109A1 (en) | 2015-01-22 |
| US10064851B2 (en) | 2018-09-04 |
| WO2007150064A3 (en) | 2008-02-21 |
| MX2009000032A (es) | 2009-01-23 |
| US20170027919A1 (en) | 2017-02-02 |
| EP2040548A4 (en) | 2009-12-23 |
| WO2007150064A2 (en) | 2007-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE555788T1 (de) | Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität | |
| Madhyastha et al. | MicroRNA signature in diabetic wound healing: promotive role of miR‐21 in fibroblast migration | |
| ATE516353T1 (de) | Verwendung von rnai mit inhibierender parp aktivität zur herstelllung eines arzneimittels zur behandlung von krebs | |
| MX2020011746A (es) | Terapias genicas para los trastornos lisosomales. | |
| PH12020500203A1 (en) | Identification of lkb1 mutation as a predictive boimarker for sensitivity to tor kinase inhibitors | |
| MX2010004074A (es) | Combinacion 059. | |
| MX2021012184A (es) | Terapias genicas para trastornos lisosomales. | |
| CY1108927T1 (el) | Αναστολεις μιτωτικης κινεσινης | |
| MX352412B (es) | Tratamiento de enfermedades relacionadas con eritropoyetina (epo) mediante inhibicion del transcrito antisentido natural a eritropoyetina. | |
| EA201170847A1 (ru) | Тиазолопиридиновые соединения, регулирующие сиртуин | |
| ATE446094T1 (de) | Mitotische kinesin-hemmer | |
| EP2493507A4 (en) | AX213 AND AX132 PCSK9 ANTAGONISTS AND VARIANTS THEREOF | |
| DE60324449D1 (de) | Inhibitoren der phosphodiesterase der zyklischen n, und deren verwendung in therapie | |
| MX2010012860A (es) | Metodos para tratar cancer del sistema nervioso central. | |
| Wu et al. | Pressure and inflammatory stimulation induced increase of cadherin-11 is mediated by PI3K/Akt pathway in synovial fibroblasts from temporomandibular joint | |
| Chen et al. | Botulinum toxin type A-targeted SPP1 contributes to neuropathic pain by the activation of microglia pyroptosis | |
| GT200500215A (es) | Amidas sustituidas de àcido tienopirrolcarboxìlico, amidas del àcido pirrolotiazolcarboxìlico y anàlogos relacionados como inhibidores de la epsilon caseìna quinasa i | |
| MX2011012596A (es) | Metodos para incrementar os efectos de un inhibidor selectivo de la recaptacion de serotonina en los mamiferos. | |
| WO2010065536A3 (en) | Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases | |
| ATE529514T1 (de) | Sirna zur hemmung der il-6-expression und diese enthaltende zusammensetzung | |
| MX2023009151A (es) | Composiciones para el tratamiento de afecciones y enfermedades asociadas con la expresion de policistina. | |
| ATE554069T1 (de) | Verwendung von tetrahydropyridinen zur behandlung von erkrankungen des zentralnervensystems | |
| EA202192737A1 (ru) | Генная терапия лизосомальных нарушений | |
| MX2024001673A (es) | Metodo de tratamiento del trastorno por estres postraumatico. | |
| Kohl et al. | Deep Brain Stimulation for Alcoholism |